Maaz Syed Ahmed, MD
Nephrology · Round Rock, TXNPI 1790947927
Payments from drug & device makers
What this record shows
6 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 46.9% of the total. Reporting peaked in 2024 at $85 and has fallen 76.1% since, to $20 in 2025. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.
Across 6 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$71
- Amgen$20
- Nxstage Medical, Inc.$18
- Vifor Pharma, Inc.$16
- Smith+Nephew$14
- Natus Medical Incorporated$13
What the payments were for
- Food & beverage$8153%
- Education$7147%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 1 | $71 |
| Amgen | 1 | $20 |
| Nxstage Medical, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $14 |
| Natus Medical Incorporated | 1 | $13 |
How this compares
$152 in reported general payments places this provider in the 10th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $56,136 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $18,572 |
| Sevelamer Carbonate | 23 | $5,191 |
| Calcitriol | 174 | $4,950 |
| Calcium Acetate | 27 | $2,248 |
| Losartan Potassium | 149 | $1,845 |
| Torsemide | 55 | $1,392 |
| Cinacalcet Hcl | 17 | $1,232 |
| Tamsulosin Hcl | 54 | $1,188 |
| Spironolactone | 72 | $1,121 |
| Carvedilol | 66 | $921 |
| Lisinopril | 86 | $860 |
| Amlodipine Besylate | 104 | $676 |
| Allopurinol | 81 | $647 |
| Hydralazine Hcl | 38 | $493 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Round Rock
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.